Interim report, foreign filer
Open the filing on sec.gov
Cellectis S.A. (CLLS)
Nasdaq: CLLS · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2014
The companyfiscal 2025, as filed
Revenue$72.9M+75.8%
Net income-$67.6M-83.9%
Earnings per share$-0.67-63.4%
Operating cash flow-$39.4M-271.4%
Cash$61.5M-57.0%
Debtn/a
Shareholders’ equity$75.9M-42.1%
Shares, diluted100.3M+10.7%
Return on equity-89.0%
The recordfrom its filings
Filings in 202630
Newest filingNov 13 · 6-K
Annual reportMar 20, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted115
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer, amended
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.